Photo of Rupal S. Bhatt,  MD, PhD

Rupal S. Bhatt, MD, PhD

Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center
Phone: (617) 667-2131


rbhatt@bidmc.harvard.edu

Rupal S. Bhatt, MD, PhD

Beth Israel Deaconess Medical Center

EDUCATIONAL TITLES

  • Assistant Professor, Medicine, Harvard Medical School
  • Clinical Fellow, Hematology-Oncology, Beth Israel Deaconess Medical Center

DF/HCC PROGRAM AFFILIATION

Publications

Powered by Harvard Catalyst
  • McKay RR, Rodriguez GE, Lin X, Kaymakcalan MD, Hamnvik OP, Sabbisetti VS, Bhatt RS, Simantov R, Choueiri TK. Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. Clin Cancer Res 2015. PubMed
  • Plymate SR, Bhatt RS, Balk SP. Taxane resistance in prostate cancer mediated by AR-independent GATA2 regulation of IGF2. Cancer Cell 2015; 27:158-9. PubMed
  • McDermott DF, Cheng SC, Signoretti S, Margolin KA, Clark JI, Sosman JA, Dutcher JP, Logan TF, Curti BD, Ernstoff MS, Appleman L, Wong MK, Khushalani NI, Oleksowicz L, Vaishampayan UN, Mier JW, Panka DJ, Bhatt RS, Bailey AS, Leibovich BC, Kwon ED, Kabbinavar FF, Belldegrun AS, Figlin RA, Pantuck AJ, Regan MM, Atkins MB. The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. Clin Cancer Res 2015; 21:561-8. PubMed
  • Zhang L, Wang X, Bullock AJ, Callea M, Shah H, Song J, Moreno K, Visentin B, Deutschman D, Alsop DC, Atkins MB, Mier JW, Signoretti S, Bhasin M, Sabbadini RA, Bhatt RS. Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer. Clin Cancer Res 2015. PubMed
  • Bhatt RS, Atkins MB. Molecular Pathways: Can Activin-Like Kinase Pathway Inhibition Enhance the Limited Efficacy of VEGF Inhibitors? Clin Cancer Res 2014. PubMed
  • Wang X, Bullock AJ, Zhang L, Wei L, Yu D, Mahagaokar K, Alsop DC, Mier JW, Atkins MB, Coxon A, Oliner J, Bhatt RS. The Role of Angiopoietins as Potential Therapeutic Targets in Renal Cell Carcinoma. Transl Oncol 2014. PubMed
  • Beddy P, Genega EM, Ngo L, Hindman N, Wei J, Bullock A, Bhatt RS, Atkins MB, Pedrosa I. Tumor necrosis on magnetic resonance imaging correlates with aggressive histology and disease progression in clear cell renal cell carcinoma. Clin Genitourin Cancer 2014; 12:55-62. PubMed
  • Wang X, Zhang L, O'Neill A, Bahamon B, Alsop DC, Mier JW, Goldberg SN, Signoretti S, Atkins MB, Wood CG, Bhatt RS. Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts. Br J Cancer 2013; 108:319-26. PubMed
  • Bhatt RS, Wang X, Zhang L, Collins MP, Signoretti S, Alsop DC, Goldberg SN, Atkins MB, Mier JW. Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling. Mol Cancer Ther 2010; 9:2793-802. PubMed
  • Bhatt RS, Merchan J, Parker R, Wu HK, Zhang L, Seery V, Heymach JV, Atkins MB, McDermott D, Sukhatme VP. A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma. Cancer 2010; 116:1751-6. PubMed
  • Cho DC,Puzanov I,Regan MM,Schwarzberg T,Seery V,Lee MY,Liu V,Bhatt R,Koon H,Mier JW,Sosman JA,Atkins MB,McDermott DF. Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma. J Immunother 2009; 32:181-5. PubMed
  • Bhatt RS,Bubley GJ. The challenge of herbal therapies for prostate cancer. Clin Cancer Res 2008; 14:7581-2. PubMed
  • Bhatt RS, Landis DM, Zimmer M, Torregrossa J, Chen S, Sukhatme VP, Iliopoulos O, Balk S, Bubley GJ. Hypoxia-inducible factor-2alpha: effect on radiation sensitivity and differential regulation by an mTOR inhibitor. BJU Int 2008; 102:358-63. PubMed
  • Gallagher DC, Bhatt RS, Parikh SM, Patel P, Seery V, McDermott DF, Atkins MB, Sukhatme VP. Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak. Clin Cancer Res 2007; 13:2115-20. PubMed
  • Bhatt RS, Seth P, Sukhatme VP. Biomarkers for monitoring antiangiogenic therapy. Clin Cancer Res 2007; 13:777s-780s. PubMed
  • Bhatt RS, Zhang L, Bullock A, Moreno K, Signoretti S, Atkins M, Sabbadini R, Mier J. Sphingosine-1-phosphate (S1P) as a novel target in renal cancer (RCC). 2010.
  • Bhatt R, Wang X, Zhang L, Bhasin M, Libermann T, O’Neil A, Signoretti S, Atkins M, Mier J, Goldberg SN. Cox-2 inhibition delays resistance to sunitinib in RCC xenograft models. 2009.
  • Bullock AJ, Zhang L, AM O’Neill, Percy A, Sukhatme V, Mier JW, Atkins MB, Bhatt RS. Plasma angiopoietin-2 (ANG2) as an angiogenic biomarker in renal cell carcinoma (RCC) 2010.
Hide